For those who might have missed it, the results from the preceding Single Ascending Dose (SAD) trial were published late last year:

First-in-human assessment of PRX2, an anti–α-synuclein monoclonal antibody, in healthy volunteers - Schenk - 216 - Movement Disorders - Wiley Online Library

(this is an open-access document)

and here is the trial record for the recently-completed Multiple Ascending Dose (MAD) trial:

Multiple Ascending Dose Study of PRX2 in Patients With Parkinson's Disease - Full Text View - ClinicalTrials.gov